Metastatic Castration-Resistant Prostate Cancer
T.O.A.D. Oncology S.A. focuses on metastatic castration-resistant prostate cancer, with particular attention to disease settings in which PSMA-expressing tumors are being targeted for treatment.
- Prostate Cancer
- PSMA-Expressing Tumors
- Advanced Urologic Oncology
The sponsor’s current research activity is centered on therapeutic development for advanced prostate malignancy, reflecting interest in treatment options for difficult-to-manage androgen-resistant disease.
Oncology Drug Development
The company’s clinical research portfolio is rooted in oncology, with emphasis on evaluating investigational agents designed for tumor-directed activity in advanced cancer.
- Investigational Anticancer Therapy
- Tumor-Targeted Treatment
- Solid Tumor Oncology
Its funded study activity highlights a specific interest in novel anticancer compounds for patients with unmet needs in solid tumor management.
Safety and Tolerability Assessment
Clinical evaluation is directed toward the safety and tolerability of an investigational treatment, with attention to identifying clinically acceptable administration approaches.
- Adverse Event Monitoring
- Tolerability Profiling
- Clinical Safety
This area reflects a therapeutic focus on establishing treatment suitability in patients with advanced prostate cancer.
Translational Cancer Research
The sponsor is engaged in early clinical exploration of a targeted oncology candidate, linking laboratory-derived concepts with patient-focused cancer treatment development.
- Targeted Therapy
- First-in-Human Oncology Studies
- Biomarker-Driven Cancer Treatment
Its research interest includes advancing a precision oncology approach in prostate malignancy through clinical assessment of a new therapeutic agent.
